secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-020604
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q4 net loss $38.3M; cash $719.9M; NVL-520 gets FDA BTD
-----------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $719.9M at Dec 31, 2023; operating runway into 2027.
- Q4 net loss $38.3M, full year 2023 net loss $126.2M; R&D expenses $35.6M Q4 and $113.2M full year.
- FDA granted Breakthrough Therapy Designation to NVL-520 for ROS1+ NSCLC after 2+ prior TKIs.
- Initiated Phase 2 of ALKOVE-1 trial for NVL-655 at 150 mg once daily with registrational intent.
- Expect to initiate Phase 1 for HER2 program in 2024; promoted Matthew Metivier to SVP HR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/0000950170-24-020604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/nuvl-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer